Guanfacine as a potential preventive therapy for chronic migraine: a mechanistic hypothesis
Abstract
Background: Despite the recent therapeutic advances, approximately one-third of patients with chronic migraine fail to achieve clinically meaningful benefit, and existing oral preventive therapies remain limited by tolerability and off-target effects. There is, therefore, a pressing need for new, well-tolerated, mechanistically distinct preventive treatments for chronic migraine. This hypothesis article evaluates the pharmacological and biological rationale supporting guanfacine as a potential preventive therapy for chronic migraine.
Hypothesis: We hypothesize that guanfacine, a selective α2A-adrenergic receptor agonist already approved for hypertension and attention-deficit/hyperactivity disorder, may have the potential to prevent chronic migraine through three biologically plausible convergent mechanisms: (1) potential presynaptic inhibition of calcium-dependent release of CGRP, glutamate, substance P, and other pro-nociceptive neuropeptides from trigeminal primary afferents; (2) potential attenuation of peripheral and central sensitization within the trigeminovascular system and the trigeminocervical complex; and (3) potential modulation of descending pain control pathways arising from the locus coeruleus and prefrontal cortex. This hypothesis is supported by evidence linking the ADRA2B gene to trigeminal nerve disorders, by recently published randomized controlled trial data demonstrating enhanced analgesia when guanfacine is added to lidocaine for trigeminal nerve…
Read the paper
Related studies
- Calcium Ions in the Physiology and Pathology of the Central Nervous System
- AI-powered in silico twins: redefining precision medicine through simulation, personalization, and predictive healthcare
- In silico functional, structural and pathogenicity analysis of missense single nucleotide polymorphisms in human MCM6 gene
- In Silico drug repurposing pipeline using deep learning and structure based approaches in epilepsy
- Targeting serotonin receptors with phytochemicals – an in-silico study
- In silico exploration of anti-prostate cancer compounds from differential expressed genes
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.